Literature DB >> 27978991

Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.

Amrita V Kamath1.   

Abstract

Monoclonal antibodies (mAbs) are an important therapeutic class with complex pharmacology and interdependent pharmacokinetic (PK) and pharmacodynamics (PD) properties. Understanding the PK and PD of mAbs and their biological and mechanistic underpinnings are crucial in enabling their design and selection, designing appropriate efficacy and toxicity studies, translating PK/PD parameters to humans, and optimizing dose and regimen to maximize success in the clinic. Significant progress has been made in this field however many critical questions still remain. This article gives a brief overview of the PK and PD of mAbs, factors that influence them, and areas of ongoing inquiry. Current tools and translational approaches to predict the PK/PD of mAbs in humans are also discussed.
Copyright © 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27978991     DOI: 10.1016/j.ddtec.2016.09.004

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN: 1740-6749


  37 in total

1.  A potent antagonist antibody targeting connexin hemichannels alleviates Clouston syndrome symptoms in mutant mice.

Authors:  Yuanyuan Kuang; Veronica Zorzi; Damiano Buratto; Gaia Ziraldo; Flavia Mazzarda; Chiara Peres; Chiara Nardin; Anna Maria Salvatore; Francesco Chiani; Ferdinando Scavizzi; Marcello Raspa; Min Qiang; Youjun Chu; Xiaojie Shi; Yu Li; Lili Liu; Yaru Shi; Francesco Zonta; Guang Yang; Richard A Lerner; Fabio Mammano
Journal:  EBioMedicine       Date:  2020-06-15       Impact factor: 8.143

2.  Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis.

Authors:  Antoine Guillon; Jeoffrey Pardessus; Pierre Lhommet; Christelle Parent; Renaud Respaud; Denis Marchand; Jérôme Montharu; Michèle De Monte; Philip Janiak; Christophe Boixel; Héloïse Audat; Sylvain Huille; Etienne Guillot; Nathalie Heuze-Vourc'h
Journal:  MAbs       Date:  2019-02-04       Impact factor: 5.857

3.  Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.

Authors:  Xiaoying Chen; Vahid Farrokhi; Pratap Singh; Mireia Fernandez Ocana; Jenil Patel; Lih-Ling Lin; Hendrik Neubert; Joanne Brodfuehrer
Journal:  MAbs       Date:  2017-11-30       Impact factor: 5.857

Review 4.  Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.

Authors:  David Ternant; Nicolas Azzopardi; William Raoul; Theodora Bejan-Angoulvant; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

5.  Protein painting, an optimized MS-based technique, reveals functionally relevant interfaces of the PD-1/PD-L1 complex and the YAP2/ZO-1 complex.

Authors:  Amanda Haymond; Douglass Dey; Rachel Carter; Angela Dailing; Vaishnavi Nara; Pranavi Nara; Sravani Venkatayogi; Mikell Paige; Lance Liotta; Alessandra Luchini
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

6.  Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?

Authors:  Nadiya Hussain; Muntaha Naeem; David J Pinato
Journal:  Hum Vaccin Immunother       Date:  2020-06-23       Impact factor: 3.452

7.  Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.

Authors:  Amit Khatri; Sandra Goss; Ping Jiang; Heikki Mansikka; Ahmed A Othman
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

8.  A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.

Authors:  Dongfen Yuan; Frederik Rode; Yanguang Cao
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

9.  Peptide-based PET quantifies target engagement of PD-L1 therapeutics.

Authors:  Dhiraj Kumar; Ala Lisok; Elyes Dahmane; Matthew McCoy; Sagar Shelake; Samit Chatterjee; Viola Allaj; Polina Sysa-Shah; Bryan Wharram; Wojciech G Lesniak; Ellen Tully; Edward Gabrielson; Elizabeth M Jaffee; John T Poirier; Charles M Rudin; Jogarao Vs Gobburu; Martin G Pomper; Sridhar Nimmagadda
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808

10.  Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity.

Authors:  Farideh Ordikhani; Mayuko Uehara; Vivek Kasinath; Li Dai; Siawosh K Eskandari; Baharak Bahmani; Merve Yonar; Jamil R Azzi; Yousef Haik; Peter T Sage; George F Murphy; Nasim Annabi; Tobias Schatton; Indira Guleria; Reza Abdi
Journal:  JCI Insight       Date:  2018-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.